The use of point-of-care evidence-based medicine (POC-EBM) resources, such as UpToDate ®, is widespread. There are concerns, however, regarding the presence of physician-industry interactions and financial conflicts of interest (FCOI) among contributors to articles. In particular, it is unclear the extent to which articles on UpToDate ® regarding inflammatory bowel disease (IBD) have these potential conflicts of interest. Aims: To investigate the prevalence of industry payments from pharmaceutical companies making biologic medications for IBD among contributors to UpToDate articles on the treatment of IBD. Methods: We conducted a cross-sectional analysis of UpToDate ® articles related to the treatment of Crohn's disease and ulcerative colitis that recommended the use of biologic medications. We collected the names of the contributors (authors, section editors, and deputy editors), and their disclosures on UpToDate were recorded. We then searched the names of those contributors on the Center for Medicare and Medicaid Open Payments (CMS-OP) database and compared the payment information from 2013 -2016 with the disclosures on UpToDate ® . We presented data per episode, rather than by individual contributor. An episode describes one instance of participation in a by one person in one article, regardless of whether an author was present on multiple articles. Results: We identified a total of 23 articles on the treatment of Crohn's disease and ulcerative colitis that recommended the use of biologic medication, with a total of 86 episodes. Among these, we found that there were 42 (48.8%) declarations of FCOI, with 40 (46.5%) that were related to the company marketing the biologic recommended in the article. When examining the CMS-OP database for the relevant years, we found 39 (45.3%) records. The median value of all industry payments was 23 349.44 (USD). In addition, there were 35 episodes of industry payments that were related to the biologic mentioned in the article, with a median value of 41 656.00 (USD). Conclusions: Our results highlight a startling high prevalence of FCOI among a POC-EBM resource for the treatment of IBD. In particular, we found that almost half of the Downloaded from https://academic.oup.com
instances in these articles had relevant FCOI and the financial burden of related payments was substantial. Further work is needed to explore the relationships with these payments.
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